KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Income from Continuing Operations (2016 - 2025)

Neogenomics' Income from Continuing Operations history spans 16 years, with the latest figure at 9881000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 35.52% year-over-year to 9881000.0; the TTM value through Dec 2025 reached 108025000.0, down 37.22%, while the annual FY2025 figure was 108025000.0, 37.22% down from the prior year.
  • Income from Continuing Operations reached 9881000.0 in Q4 2025 per NEO's latest filing, up from 27129000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 75873000.0 in Q2 2021 to a low of 49408000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 21365850.0, with a median of 23509000.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 1211.86% in 2021 against a maximum downside of 895.78% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 41759000.0 in 2021, then soared by 45.67% to 22687000.0 in 2022, then soared by 36.85% to 14326000.0 in 2023, then dropped by 6.97% to 15324000.0 in 2024, then surged by 35.52% to 9881000.0 in 2025.
  • Per Business Quant, the three most recent readings for NEO's Income from Continuing Operations are 9881000.0 (Q4 2025), 27129000.0 (Q3 2025), and 45092000.0 (Q2 2025).